{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:09:14Z","timestamp":1787738954428,"version":"build-2784847793"},"reference-count":49,"publisher":"Impact Journals, LLC","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,5,17]]},"DOI":"10.18632\/oncotarget.8667","type":"journal-article","created":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T12:56:09Z","timestamp":1460206569000},"page":"29102-29115","source":"Crossref","is-referenced-by-count":21,"title":["Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia\/lymphoma"],"prefix":"10.18632","volume":"7","author":[{"given":"Minjie","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gege","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houcai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqian","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangning","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojie","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"},{"name":"College of Life Science and Technology, Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,4,9]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/leu.2013.366","article-title":"Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia","volume":"28","author":"Furukawa","year":"2014","journal-title":"Leukemia"},{"key":"2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2013.10.011","article-title":"Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines","volume":"38","author":"Konstantinov","year":"2014","journal-title":"Leuk Res"},{"key":"3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/leu.2012.192","article-title":"Glucocorticoid sensitivity of T-cell lymphoblastic leukemia\/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression","volume":"27","author":"Talora","year":"2013","journal-title":"Leukemia"},{"key":"4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12185-011-0899-3","article-title":"Critical roles of NOTCH1 in acute T-cell lymphoblastic leukemia","volume":"94","author":"Pear","year":"2011","journal-title":"Int J Hematol"},{"key":"5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/17474086.2013.827415","article-title":"The Bcl-2\/Bax and Ras\/Raf\/MEK\/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches","volume":"6","author":"Casale","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/leu.2013.349","article-title":"Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling","volume":"28","author":"Locatelli","year":"2014","journal-title":"Leukemia"},{"key":"7","first-page":"101","article-title":"Anisomycin induces apoptosis of glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells via activation of mitogen-activated protein kinases p38 and JNK","volume":"60","author":"Zhu","year":"2013","journal-title":"Neoplasma"},{"key":"8","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1016\/j.febslet.2013.06.011","article-title":"ATF4 activation by the p38MAPK-eIF4E axis mediates apoptosis and autophagy induced by selenite in Jurkat cells","volume":"587","author":"Xu","year":"2013","journal-title":"FEBS Lett"},{"key":"9","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1084\/jem.20110580","article-title":"Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias","volume":"208","author":"Basso","year":"2011","journal-title":"J Exp Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/ng.924","article-title":"Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia","volume":"43","author":"Toribio","year":"2011","journal-title":"Nat Genet"},{"key":"11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clon.2013.11.022","article-title":"Bortezomib in multiple myeloma: a practice guideline","volume":"26","author":"Cancer Care Ontario Hematology Disease Site","year":"2014","journal-title":"Clin Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.seminoncol.2013.07.005","article-title":"Novel generation of agents with proven clinical activity in multiple myeloma","volume":"40","author":"San Miguel","year":"2013","journal-title":"Semin Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1158\/1078-0432.CCR-12-1213","article-title":"Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy","volume":"18","author":"Johnson","year":"2012","journal-title":"Clin Cancer Res"},{"key":"14","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Adams","year":"2013","journal-title":"Clin Cancer Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1464-410X.2012.11647.x","article-title":"The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers","volume":"111","author":"Kiltie","year":"2013","journal-title":"BJU Int"},{"key":"16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5507\/bp.2013.085","article-title":"Histone deacetylase inhibitors in cancer therapy. A review","volume":"158","author":"Eckschlager","year":"2014","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","article-title":"Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma","volume":"16","author":"Vu","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/1535-7163.MCT-12-0811","article-title":"Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus","volume":"12","author":"Chiang","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3892\/mmr_00000305","article-title":"Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA","volume":"3","author":"Zuo","year":"2010","journal-title":"Mol Med Rep"},{"key":"20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1535-7163.MCT-08-0534","article-title":"Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models","volume":"8","author":"Eckhardt","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"21","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/1078-0432.CCR-12-1511","article-title":"Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K\/AKT, and NF-kappaB","volume":"19","author":"Shalapour","year":"2013","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2141.2011.08591.x","article-title":"Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-kappaB and Bim","volume":"153","author":"Grant","year":"2011","journal-title":"Br J Haematol"},{"key":"23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00277-011-1175-6","article-title":"Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells","volume":"90","author":"Li","year":"2011","journal-title":"Ann Hematol"},{"key":"24","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.juro.2012.07.108","article-title":"Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells","volume":"188","author":"Asano","year":"2012","journal-title":"J Urol"},{"key":"25","first-page":"2407","article-title":"Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors","volume":"32","author":"Hedman","year":"2012","journal-title":"Anticancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jinorgbio.2012.04.007","article-title":"Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells","volume":"113","author":"Perego","year":"2012","journal-title":"J Inorg Biochem"},{"key":"27","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Anderson","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/OTT.S28911","article-title":"Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma","volume":"5","author":"Schots","year":"2012","journal-title":"Onco Targets Ther"},{"key":"29","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Orlowski","year":"2007","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1182\/blood-2007-12-129833","article-title":"Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents inandmodels of B-cell lymphoma","volume":"111","author":"O\u2032Connor","year":"2008","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1358\/dot.2013.49.3.1939264","article-title":"Carfilzomib for the treatment of multiple myeloma","volume":"49","author":"Mazumder","year":"2013","journal-title":"Drugs Today (Barc)"},{"key":"32","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1535-7163.MCT-10-1108","article-title":"Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cellsand","volume":"10","author":"Grant","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"33","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1182\/blood-2009-12-257261","article-title":"The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cellsand","volume":"115","author":"Grant","year":"2010","journal-title":"Blood"},{"key":"34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/abbs\/gmu030","article-title":"Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells","volume":"46","author":"Shi","year":"2014","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"35","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1158\/1535-7163.MCT-14-0220","article-title":"andinteractions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells","volume":"13","author":"Grant","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"36","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/leu.2009.41","article-title":"The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis","volume":"23","author":"Zhao","year":"2009","journal-title":"Leukemia"},{"key":"37","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s10495-007-0063-y","article-title":"SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib","volume":"12","author":"Tesoriere","year":"2007","journal-title":"Apoptosis"},{"key":"38","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","article-title":"Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors","volume":"10","author":"Grant","year":"2004","journal-title":"Clin Cancer Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2006-03-013128","article-title":"NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells","volume":"110","author":"Chandra","year":"2007","journal-title":"Blood"},{"key":"40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.yexcr.2004.02.001","article-title":"The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib","volume":"295","author":"Grant","year":"2004","journal-title":"Exp Cell Res"},{"key":"41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/mc.21835","article-title":"Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage","volume":"52","author":"Pollack","year":"2013","journal-title":"Mol Carcinog"},{"key":"42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0609.2007.00995.x","article-title":"Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma","volume":"80","author":"Sezer","year":"2008","journal-title":"Eur J Haematol"},{"key":"43","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1600-0609.2009.01239.x","article-title":"Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma","volume":"82","author":"Sezer","year":"2009","journal-title":"Eur J Haematol"},{"key":"44","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jtcvs.2004.07.010","article-title":"Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species","volume":"128","author":"Jones","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"45","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2007-08-105601","article-title":"Combination of proteasome inhibitors bortezomib and NPI-0052 triggersynergistic cytotoxicity in multiple myeloma","volume":"111","author":"Anderson","year":"2008","journal-title":"Blood"},{"key":"46","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbrc.2013.03.009","article-title":"Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models","volume":"433","author":"Kohno","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"47","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.bbrc.2005.11.131","article-title":"Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death","volume":"339","author":"Kohno","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"48","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.bbrc.2009.12.086","article-title":"Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib","volume":"391","author":"Kohno","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/jcp.21444","article-title":"Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells","volume":"216","author":"Ciardiello","year":"2008","journal-title":"J Cell Physiol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.8667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T16:11:22Z","timestamp":1718467882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.8667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,9]]},"references-count":49,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2016,5,17]]}},"alternative-id":["8667","27074555"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.8667","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,9]]}}}